Financial results for the year
ended March 31, 2023
- Supplement > May 10, 2023
- Financial results and forecast
- Revenue by segment
- Management index
- Capital investments and Depreciation and Amortization
- R&D expenses
- Employees
- Consolidated statement of profit or loss
- Consolidated statement of financial position
- Quarterly trend for FY2021 and FY2022
- Group Companies
- Pipeline (as of May 10, 2023)
1. Financial results and forecast
|
FY2021 |
FY2022 |
FY2023 |
|
|
actual |
actual |
forecast |
|
|
Revenue |
335.1 |
426.7 |
450.0 |
|
change % |
12.8 |
27.3 |
5.5 |
|
Operating profit |
110.3 |
149.0 |
150.0 |
|
change % |
(6.1) |
35.1 |
0.7 |
|
Profit before tax |
126.3 |
220.3 |
192.5 |
|
change % |
(11.7) |
74.5 |
(12.6) |
|
Profit attributable to owners of parent |
114.2 |
185.0 |
155.0 |
|
change % |
2.1 |
62.0 |
(16.2) |
Note: Change % shows changes from the same period of the previous fiscal year.
Change
|
FY2022 |
FY2023 |
|
91.5 |
23.3 |
|
38.7 |
1.0 |
|
94.1 |
(27.8) |
|
70.8 |
(30.0) |
(Billions of yen) FY2023 1H
forecast
217.0
43.9
80.5
185.2
98.0
44.2
78.0
36.2
|
FY2021 |
FY2022 |
FY2023 |
|
|
actual |
actual |
forecast |
|
|
Prescription drugs |
89.1 |
75.0 |
134.1 |
|
change % |
(5.9) |
(15.8) |
78.7 |
|
INTUNIV |
16.4 |
19.2 |
－ |
|
VYVANSE |
0.8 |
1.4 |
－ |
|
Infectious Disease Drugs |
11.8 |
7.4 |
65.7 |
|
CYMBALTA |
15.9 |
5.4 |
4.2 |
|
OXYCONTIN Franchise |
4.8 |
4.4 |
4.1 |
|
SYMPROIC |
2.7 |
3.4 |
4.9 |
|
ACTAIR |
0.5 |
0.5 |
1.0 |
|
MULPLETA |
0.1 |
0.1 |
0.1 |
|
PIRESPA |
3.8 |
2.5 |
1.9 |
|
Others |
32.4 |
30.6 |
52.1 |
|
CRESTOR |
5.9 |
4.1 |
－ |
|
Overseas subsidiaries/Export |
34.4 |
42.5 |
96.6 |
|
change % |
39.5 |
23.7 |
127.3 |
|
Shionogi Inc. |
13.8 |
15.4 |
13.6 |
|
Ping An-Shionogi / C&O |
10.2 |
12.0 |
58.0 |
|
Shionogi B.V. |
5.0 |
9.1 |
11.5 |
|
Contract manufacturing |
17.4 |
15.3 |
13.8 |
|
change % |
(11.7) |
(12.0) |
(10.1) |
|
OTC and quasi-drugs |
11.2 |
13.1 |
15.0 |
|
change % |
(4.8) |
17.7 |
14.2 |
|
Royalty income |
181.3 |
174.7 |
189.5 |
|
change % |
25.3 |
(3.6) |
8.5 |
|
HIV Franchise |
174.0 |
168.5 |
185.0 |
|
CRESTOR |
1.2 |
1.3 |
－ |
|
Others |
6.1 |
4.9 |
4.5 |
|
COVID-19 related products |
－ |
104.7 |
－ |
|
change % |
－ |
－ |
－ |
|
Others |
1.8 |
1.3 |
1.0 |
|
change % |
1.7 |
(28.8) |
(21.6) |
|
Total |
335.1 |
426.7 |
450.0 |
|
change % |
12.8 |
27.3 |
5.5 |
Change
|
FY2022 |
FY2023 |
|
(14.1) |
59.1 |
|
2.8 |
(19.2) |
|
0.6 |
(1.4) |
|
(4.4) |
58.3 |
|
(10.5) |
(1.3) |
|
(0.4) |
(0.3) |
|
0.7 |
1.5 |
|
0.0 |
0.5 |
|
(0.0) |
0.0 |
|
(1.3) |
(0.6) |
|
(1.8) |
21.5 |
|
(1.8) |
(4.1) |
|
8.1 |
54.1 |
|
1.7 |
(1.8) |
|
1.8 |
46.0 |
|
4.1 |
2.5 |
|
(2.1) |
(1.5) |
|
2.0 |
1.9 |
|
(6.6) |
14.8 |
|
(5.5) |
16.5 |
|
0.2 |
(1.3) |
|
(1.2) |
(0.4) |
|
104.7 |
(104.7) |
|
(0.5) |
(0.3) |
|
91.5 |
23.3 |
(Billions of yen) FY2023 1H
forecast
87.4
162.1
－
－
40.0
2.1
2.1
2.3
0.4
0.1
1.1
39.3
－
28.0
40.5
6.7
13.2
5.4
7.3
(0.4)
6.8
8.6
86.9
4.4
86.0
－
0.9
－
－
0.5
(17.4)
217.0
43.9
Note: Change % shows changes from the same period of the previous fiscal year. Sales of prescription drugs are shown on non-consolidated basis. Products included in infectious disease drugs are bellow.
・Xofluza ・Rapiacta ・Brightpoc Flu Neo ・Finibax ・Flumarin ・Flomox ・Shiomarin ・Vancomycin ・Baktar ・Flagyl・Isodine
COVID-19 related products : Revenue from XOCOVA and S-268019
Infectious Disease Drugs for FY2023 forecast include COVID-19 related products.
Others of Prescription drugs for FY2023 forecast include one-time payment related to transfer of ADHD assets to Takeda.
3. Management index
( Management index trend )
|
FY2020 |
FY2021 |
FY2022 |
||
|
Return on equity attributable to owners of parent |
% |
13.9 |
12.5 |
17.8 |
|
(ROE) |
||||
|
Ratio of profit before tax to total assets (ROA) |
% |
15.3 |
11.7 |
17.9 |
|
Ratio of operating profit to revenue |
% |
39.5 |
32.9 |
34.9 |
|
Ratio of profit before tax to revenue |
% |
48.1 |
37.7 |
51.6 |
|
Total assets turnover |
0.32 |
0.31 |
0.35 |
|
|
Ratio of equity attributable to owners of parent to |
% |
84.7 |
84.8 |
83.9 |
|
total assets |
||||
|
Dividend payout ratio |
% |
29.6 |
30.4 |
21.7 |
|
Ratio of dividends to equity attributable to |
% |
4.1 |
3.8 |
3.9 |
|
owners of parent (DOE) |
||||
|
Basic earnings per share |
yen |
365.03 |
378.75 |
621.31 |
|
Diluted earnings per share |
yen |
364.89 |
378.63 |
621.10 |
Disclaimer
Shionogi & Co. Ltd. published this content on 10 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2023 04:15:08 UTC.
Publicnow 2023
|
|
|
|
|
|
|
|
|
|
||||
|
||||
Technical analysis trends SHIONOGI & CO., LTD.
| Short Term | Mid-Term | Long Term | |
| Trends | Bullish | Bearish | Bearish |
Income Statement Evolution
|
Sell  Buy |
|
| Mean consensus | OUTPERFORM |
| Number of Analysts | 14 |
| Last Close Price | 6 295,00 JPY |
| Average target price | 7 610,71 JPY |
| Spread / Average Target | 20,9% |
